Novo Nordisk’s Guidance Raise Wasn’t Enough: The Lingering Challenges That Drove Shares Lower
Despite Q2 beat and raise, Novo shares dropped on flat 2026 outlook, DKK 6.3B impairment, ZEUS failure and fierce Lilly competition.
Despite Q2 beat and raise, Novo shares dropped on flat 2026 outlook, DKK 6.3B impairment, ZEUS failure and fierce Lilly competition.
Analysts say Lilly’s retatrutide, heading for 2027 FDA filing after strong trials, could hit $3.8B sales by 2030 and help keep its edge over Novo Nordisk.
Abivax has resumed partnership talks with major pharma companies via Centerview Partners while preparing a potential independent U.S. launch of obefazimod.
Eli Lilly secures BPL-003 and other novel psychedelic-inspired treatments designed to provide rapid, long-lasting relief for treatment-resistant depression.
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Novo Nordisk’s Wegovy pill is dominating early sales with 8x more prescriptions than Eli Lilly’s Foundayo.